Large randomized trials have confirmed the cardiorenal benefits from sodium-glucose
transporter 2 (SGLT2) inhibitors for patients with type 2 diabetes (T2D), for patients
with chronic heart failure and reduced ejection fraction (HFrEF), and for patients
with chronic kidney disease (CKD). However, whether these cardiorenal benefits vary
in different chronic diseases or vary with specific SGLT2 inhibitors remains unclear.
Thus, we conducted this meta-analysis based on cardiovascular and renal outcome trials
of SGLT2 inhibitors, and aimed at exploring the differences in the cardiorenal benefits
from four SGLT2 inhibitors in three chronic diseases.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med. 2020;
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020;
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.N Engl J Med. 2020;
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med. 2019; 381: 1995-2008
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019; 380: 347-357
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.N Engl J Med. 2017; 377: 644-657
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015; 373: 2117-2128
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.Lancet. 2020;
Article info
Publication history
Published online: January 20, 2021
Accepted:
January 7,
2021
Received in revised form:
December 27,
2020
Received:
October 23,
2020
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
